Sweis RF - Search Results

1

A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.

Desai KB, Serritella AV, Stadler WM, O'Donnell PH, Sweis RF, Szmulewitz RZ. Desai KB, et al. Among authors: sweis rf. Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636. Online ahead of print. Clin Cancer Res. 2024. PMID: 38536082

2

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.

Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Sweis RF, et al. Cancer Immunol Res. 2016 Jul;4(7):563-8. doi: 10.1158/2326-6066.CIR-15-0274. Epub 2016 May 17. Cancer Immunol Res. 2016. PMID: 27197067 Free PMC article.

3

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.

Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Sweis RF, et al. Clin Genitourin Cancer. 2017 Apr;15(2):207-212. doi: 10.1016/j.clgc.2016.08.011. Epub 2016 Aug 17. Clin Genitourin Cancer. 2017. PMID: 27634566 Free PMC article. Clinical Trial.

4

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Sweis RF, et al. J Immunother Cancer. 2018 Apr 4;6(1):24. doi: 10.1186/s40425-018-0334-x. J Immunother Cancer. 2018. PMID: 29618376 Free PMC article.

5

Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma.

Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Leng J, et al. Among authors: sweis rf. Clin Genitourin Cancer. 2019 Feb;17(1):e12-e18. doi: 10.1016/j.clgc.2018.10.003. Epub 2018 Oct 12. Clin Genitourin Cancer. 2019. PMID: 30392939

6

Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.

Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Labbate C, et al. Among authors: sweis rf. J Immunother Cancer. 2019 Mar 11;7(1):66. doi: 10.1186/s40425-019-0546-8. J Immunother Cancer. 2019. PMID: 30857555 Free PMC article.

7

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.

Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Meric-Bernstam F, et al. Among authors: sweis rf. Clin Cancer Res. 2022 Feb 15;28(4):677-688. doi: 10.1158/1078-0432.CCR-21-1963. Clin Cancer Res. 2022. PMID: 34716197 Clinical Trial.

8

Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.

Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM. Sweis RF, et al. JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.18.00264. JCO Precis Oncol. 2018. PMID: 35135165 No abstract available.

9

Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.

Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Boni V, et al. Among authors: sweis rf. Clin Cancer Res. 2022 May 13;28(10):2020-2029. doi: 10.1158/1078-0432.CCR-21-3656. Clin Cancer Res. 2022. PMID: 35165101 Free PMC article. Clinical Trial.

10

Bladder-Preserving Trimodality Therapy With Capecitabine.

Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Lynch C, et al. Among authors: sweis rf. Clin Genitourin Cancer. 2024 Apr;22(2):476-482.e1. doi: 10.1016/j.clgc.2024.01.002. Epub 2024 Jan 9. Clin Genitourin Cancer. 2024. PMID: 38228414

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page